NCT03458598

Brief Summary

Objectives The primary objective is to demonstrate that in patients undergoing major urologic surgery, Patient Controlled Analgesia (PCA) opioid consumption in the first 24 hours after surgery will be significantly less in patients who have had a single shot rectus sheath block pre-operatively in addition to a post-operative rectus sheath continuous block via surgically placed catheter versus those who only have post-operative rectus sheath continuous block. Secondary outcomes will be opioid requirement intra-operatively, Numerical Rating Scale (NRS) pain scores including maximum pain score in Post Anesthesia Care Unit (PACU) and score at 24 and 48 hours, incidence and severity of nausea, number of vomiting episodes, sedation score, time to first bowel movement, time to first mobilization and duration of hospital stay.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
49

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 16, 2018

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

February 23, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

March 8, 2018

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 5, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 5, 2019

Completed
Last Updated

July 28, 2022

Status Verified

July 1, 2022

Enrollment Period

12 months

First QC Date

February 23, 2018

Last Update Submit

July 25, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Opioid requirement in first 24 hours after surgery

    Opioid requirement in first 24 hours after surgery

    24 hours

Secondary Outcomes (9)

  • Intra-operative opioid requirement

    3 - 6 hours

  • (Numerical Rating Scale) NRS pain score at 24 and 48 hours

    48 hours

  • Severity of Nausea

    48 hours

  • Number of vomiting episodes

    48 hours

  • Use of anti-emetics

    48 hours

  • +4 more secondary outcomes

Study Arms (2)

Single shot rectus sheath block

EXPERIMENTAL

The treatment group will have pre-operative ultrasound-guided single shot bilateral rectus sheath blocks with 20 ml of a ropivacaine / bupivacaine mixture per side.

Procedure: Rectus sheath blockProcedure: Bilateral rectus sheath catheterDrug: Patient controlled opioid analgesia (PCA)

Placebo Control

SHAM COMPARATOR

The control group will have a pre-operative sham ultrasound-guided subcutaneous injection of 1ml saline per side.

Procedure: Bilateral rectus sheath catheterDrug: Patient controlled opioid analgesia (PCA)Procedure: Subcutaneous injection saline placebo

Interventions

Rectus sheath block under ultrasound

Single shot rectus sheath block

A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.

Placebo ControlSingle shot rectus sheath block

Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.

Placebo ControlSingle shot rectus sheath block

Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed

Placebo Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients over 18 years
  • Undergoing major urological surgery
  • Consent to a rectus sheath blockade as part of their postoperative management

You may not qualify if:

  • Patients under 18 years
  • Local or systemic infection
  • Patients who refuse consent
  • Opioid tolerance
  • History of chronic pain
  • Psychiatric illness
  • Allergy to local anesthetic.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Alberta

Edmonton, Alberta, T6G 2G3, Canada

Location

Related Publications (5)

  • Tsui BC, Green JS, Ip VH. Ultrasound-guided rectus sheath catheter placement. Anaesthesia. 2014 Oct;69(10):1174-5. doi: 10.1111/anae.12849. No abstract available.

    PMID: 25204242BACKGROUND
  • Carney J, McDonnell JG, Ochana A, Bhinder R, Laffey JG. The transversus abdominis plane block provides effective postoperative analgesia in patients undergoing total abdominal hysterectomy. Anesth Analg. 2008 Dec;107(6):2056-60. doi: 10.1213/ane.0b013e3181871313.

    PMID: 19020158BACKGROUND
  • Siddiqui MR, Sajid MS, Uncles DR, Cheek L, Baig MK. A meta-analysis on the clinical effectiveness of transversus abdominis plane block. J Clin Anesth. 2011 Feb;23(1):7-14. doi: 10.1016/j.jclinane.2010.05.008.

    PMID: 21296242BACKGROUND
  • Dutton TJ, McGrath JS, Daugherty MO. Use of rectus sheath catheters for pain relief in patients undergoing major pelvic urological surgery. BJU Int. 2014 Feb;113(2):246-53. doi: 10.1111/bju.12316. Epub 2013 Aug 13.

    PMID: 23937574BACKGROUND
  • Tudor EC, Yang W, Brown R, Mackey PM. Rectus sheath catheters provide equivalent analgesia to epidurals following laparotomy for colorectal surgery. Ann R Coll Surg Engl. 2015 Oct;97(7):530-3. doi: 10.1308/rcsann.2015.0018.

    PMID: 26414363BACKGROUND

MeSH Terms

Conditions

Urinary Bladder NeoplasmsProstatic NeoplasmsPelvic NeoplasmsUrologic NeoplasmsPain, Postoperative

Condition Hierarchy (Ancestors)

Urogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital DiseasesGenital Neoplasms, MaleGenital Diseases, MaleGenital DiseasesProstatic DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
The intra-operative anesthesiologist, surgeon and outcomes assessor are blinded to group allocation
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 23, 2018

First Posted

March 8, 2018

Study Start

February 16, 2018

Primary Completion

February 5, 2019

Study Completion

February 5, 2019

Last Updated

July 28, 2022

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will not share

Locations